Abstract
The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. (2004). JAMA 291: 1701–1712.
Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC et al. (2006). J Natl Cancer Inst 98: 535–544.
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al. (2003). Am J Hum Genet 72: 1117–1130.
Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J et al. (2001). Gynecol Oncol 80: 341–345.
Beral V . (2003). Lancet 362: 419–427.
Beral V, Bull D, Reeves G . (2005). Lancet 365: 1543–1551.
Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL . (2002). J Natl Cancer Inst 94: 1365–1372.
Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V et al. (2004). Int J Gynecol Pathol 23: 35–40.
Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT . (2005). Gynecol Oncol 97: 457–467.
Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY . (2003). Cancer 97: 2187–2195.
Colgan TJ, Boerner SL, Murphy J, Cole DE, Narod S, Rosen B . (2002). Gynecol Oncol 85: 397–403.
Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B . (2001). Am J Surg Pathol 25: 1283–1289.
D'Andrea AD, Grompe M . (2003). Nat Rev Cancer 3: 23–34.
Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C et al. (2006). Lancet Oncol 7: 223–229.
Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K et al. (2005). J Clin Oncol 23: 7491–7496.
Eitan R, Soslow R, Lin O, Kauff ND, Liu L, Barakat RR et al. (2006). Gynecol Oncol 102: 315–318.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. (2005). Nature 434: 917–921.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A et al. (2005). J Natl Cancer Inst 97: 1652–1662.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. (1998). J Natl Cancer Inst 90: 1371–1388.
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE . (1994). Lancet 343: 692–695.
Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL et al. (2006). Breast Cancer Res 8: R15.
Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D . (1995). Obstet Gynecol 85: 304–313.
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M et al. (2006). Int J Cancer 118: 2281–2284.
Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC et al. (2002). Lancet 359: 1471–1477.
Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG et al. (1999). N Engl J Med 340: 77–84.
Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL et al. (2001). J Natl Cancer Inst 93: 1633–1637.
Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C et al. (2002). Science 297: 606–609. Epub 2002 Jun 13.
Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C et al. (2004). J Natl Cancer Inst 96: 1094–1098.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al. (2002). N Engl J Med 346: 1609–1615.
Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP . (2004). J Natl Cancer Inst 96: 1659–1668.
King MC, Marks JH, Mandell JB . (2003). Science 302: 643–646.
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K et al. (2001). Jama 286: 2251–2256.
Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH . (2005). J Clin Oncol 23: 8629–8635.
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM et al. (2004). N Engl J Med 351: 427–437.
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ et al. (1998). J Natl Cancer Inst 90: 1138–1145.
Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S et al. (2005). Clin Cancer Res 11: 5175–5180.
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al. (2002). J Clin Oncol 20: 2310–2318.
Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R et al. (2004). Gynecol Oncol 92: 521–524.
Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG et al. (2005). Lancet 365: 1769–1778.
Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D et al. (2000). J Clin Oncol 18: 2728–2732.
McEwen AR, McConnell DT, Kenwright DN, Gaskell DJ, Cherry A, Kidd AM . (2004). Gynecol Oncol 92: 992–994.
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al. (2001). N Engl J Med 345: 159–164.
Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A et al. (2005). Cancer Epidemiol Biomarkers Prev 14: 350–356.
Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U et al. (2001). N Engl J Med 345: 235–240.
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL et al. (2000). Lancet 356: 1876–1881.
Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P et al. (2002). J Natl Cancer Inst 94: 1773–1779.
Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD et al. (2006). Lancet Oncol 7: 402–406.
Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H et al. (1998). N Engl J Med 339: 424–428.
Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ et al. (2006). J Clin Oncol 24: 2437–2443.
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L et al. (2000). J Clin Oncol 18: 3360–3369.
Piver MS, Jishi MF, Tsukada Y, Nava G . (1993). Cancer 71: 2751–2755.
Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C et al. (2005). J Clin Oncol 23: 127–132.
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE et al. (2004). J Clin Oncol 22: 1055–1062. E-pub 23 February 2004.
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB et al. (2005). J Clin Oncol 23: 7804–7810. E-pub 11 October 2005.
Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L et al. (1999). J Natl Cancer Inst 91: 1475–1479.
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE et al. (2002). N Engl J Med 346: 1616–1622.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. (2002). JAMA 288: 321–333.
Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S et al. (2003). J Natl Cancer Inst 95: 1072–1078.
Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N et al. (1996). J Natl Cancer Inst 88: 1810–1820.
Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T et al. (2004). J Clin Oncol 22: 1823–1829. E-pub 5 April 2004.
The Breast Cancer Linkage Consortium (1999). J Natl Cancer Inst 91: 1310–1316.
Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H et al. (2003). Nat Med 9: 568–574.
Thompson D, Easton DF . (2002). J Natl Cancer Inst 94: 1358–1365.
Venkitaraman AR . (2002). Cell 108: 171–182.
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA et al. (2004). JAMA 292: 1317–1325.
Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ et al. (2004). Br J Cancer 91: 1911–1915.
Acknowledgements
This work was supported by the Marjorie B Cohen Foundation and the US Department of Defense (DAMD-17-03-1-0619 to SMD).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Domchek, S., Weber, B. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25, 5825–5831 (2006). https://doi.org/10.1038/sj.onc.1209881
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209881
Keywords
This article is cited by
-
What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2
Journal of Cancer Education (2015)
-
Breast Cancer Risk Gene Discovery: Opportunities and Challenges
Current Genetic Medicine Reports (2015)
-
Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?
Genome Medicine (2014)
-
Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer
Familial Cancer (2014)
-
Baseline and post prophylactic tubal–ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers
Familial Cancer (2014)